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Abstract
Background: Immunity plays an important role in controlling human papillomavirus (HPV) infection and associated
lesions. Unlike infections caused by other viruses, natural HPV infection does not always result in a protective
antibody response. Therefore, HPV antibodies are also considered markers of cumulative exposure. The aim of this
study was to identify determinants of HPV16 seroreactivity at enrollment among women from the Ludwig-McGill
cohort, a natural history study of HPV infection and risk of cervical neoplasia.
Methods: HPV16 serology was assessed by ELISA for L1 and L2 capsid antigens, while HPV typing and viral load
measurements were performed by PCR-based methods. The associations were analyzed by unconditional logistic
regression.
Results: Of 2049 subjects, 425 (20.7%) were strongly seropositive for HPV16. In multivariate analysis, seroreactivity
was positively correlated with age, lifetime number of sexual partners, frequency of sex, and HPV16 viral load, and
negatively associated with duration of smoking.
Conclusions: HPV16 seroreactivity is determined by factors that reflect viral exposure.
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Background
Persistent infection by human papillomavirus (HPV) is a
necessary cause of cervical cancer, but only a small pro-
portion of HPV positive women develop cervical lesions.
HPV infection is considered the most common sexually
transmitted infection worldwide. Most sexually active in-
dividuals are likely to be exposed to HPV infection at
some point in their lives [1]. However, most infections
seem to clear spontaneously within 12 to 24 months
[2,3] as a result of either humoral immune response or
cell mediated mechanisms [4,5].
The high frequency of HPV-related diseases in im-
munocompromised individuals underscores the import-
ant role of immune response to control HPV infection
[6]. Indeed, HPV exhibits several mechanisms to avoid
immune system recognition. HPV’s productive life cycle
is coupled to the cellular differentiation cycle of infected
host cells. As such, the most immunogenic capsid pro-
teins are only expressed in keratinocytes in the upper
layers of the epithelium where the immune system has
limited access. Moreover, the expression of early pro-
teins is maintained at very low levels [7]. Since there is
no viremia and no cell lysis upon viral shedding, the low
availability of antigens and the absence of danger signals
also contribute to keep HPV infection unknown to the
host’s immune system.
In contrast with other viral infections in which natural
exposure results in a protective antibody response, only
about half of the women infected with HPV have detect-
able levels of anti-HPV serum antibodies. Furthermore,
about half of these HPV seropositive women produce
neutralizing antibodies capable of preventing initial phases
of infection [8]. Therefore, HPV antibodies generated
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against HPV natural infections are not necessarily pro-
tective [9,5], but always work as markers of cumula-
tive exposure. High antibody titers induced by HPV
vaccines correlate with protection to HPV infections and
lesions [10,11].
The Ludwig-McGill cohort study is a longitudinal in-
vestigation of the natural history of HPV infection and
related lesions of the uterine cervix. About 2,500 women
were followed for up to 10 years. The aim of the present
study was to identify determinants of HPV16 seroreactiv-




A detailed description of the design and methods for
subject recruitment, scheduled returns, epidemiologic
data, medical procedures, and biological sampling has
been described elsewhere [12]. Briefly, 2528 women with
permanent residence in the city of Sao Paulo, Brazil,
were recruited between 1993 and 1997 and followed up
until 2005. These women attended a comprehensive ma-
ternal and child health program for low-income families
at a public hospital (Hospital e Maternidade Vila Nova
Cachoeirinha). They were between 18 and 60 years old,
had an intact uterus, no current referral for hysterec-
tomy, and did not report treatment for cervical disease
in the previous 6 months. Cervical cell specimens were
collected for cytologic and HPV DNA analyses and
blood samples were taken at each of four visits, 4-months
apart, in the first year, followed by annual and semester
visits thereafter for HPV16 serology and cervical sampling,
respectively. Subjects answered a nurse-administered ques-
tionnaire to collect information on sociodemographics,
lifestyle, and sexual, reproductive, and contraceptive char-
acteristics. Subjects gave a signed informed consent. This
study was approved by the Ludwig Institute for Cancer
Research São Paulo Branch IRB and by the IRB of the
Hospital e Maternidade Escola Vila Nova Cachoerinha
Dr Mario Altenfender, São Paulo, Brazil.
HPV Serology
Serum samples were separated from clotted blood speci-
mens and stored at −20°C until testing. An ELISA tech-
nique was used for semi-quantitative measurement of
IgG antibodies to HPV16. Recombinant HPV16 virus-
like particles, constructed with L1 capsid protein, were
prepared in the baculovirus system. An initial batch was
kindly donated by Dr. John Schiller, Laboratory of Cellular
Oncology, U.S. NIH and subsequent batches were kindly
donated by Dr. Kathryn Jansen, Merck Laboratories, USA.
The ELISA protocol was performed as described else-
where [13,14]. Briefly, polystyrene ELISA microtiter plates
were coated with 50 μL aliquots of a solution of 2 mg of
HPV16 virus-like-particles per 100 mL of PBS and incu-
bated for 1.5 hours at 37°C. Plates were washed three
times with calcium- and magnesium-free PBS and then in-
cubated with serum samples diluted 1:10 and 1:50 in PBS
containing 0.5% skim milk and 0.1% newborn calf serum
(PBS-MNCS) for 2.5 hours at 37°C. Following repeated
washings, plates were incubated for 1 hour at room
temperature with 50 μL aliquots of a conveniently diluted
(by prior block titration) peroxidase-labeled anti-IgG con-
jugate. Following an additional washing cycle, a chromo-
gen substrate mixture (0.1 mg/mL O-phenylenediamine
and 0.003% hydrogen peroxide diluted in 0.15 mol/L PBS;
pH 6.0) was added to the wells. Absorbances were read at
490 nm in a colorimetric plate reader after 45 minutes.
Replicate blank wells, with PBS-MNCS instead of diluted
serum samples, and a control human serum pool were
included in all plates. The latter was included to control
the inter- and intra-assay variation in reactivity that is
inherent to immunoenzymatic techniques. A single batch
of this serum pool (aliquoted and kept frozen at −20°C)
was prepared beforehand from dozens of blood bank and
normal clinical laboratory specimens from female adult
donors at the AC Camargo Hospital in Sao Paulo and
maintained at the Sao Paulo Branch of the Ludwig Insti-
tute for Cancer Research. An aliquot from this pool was
thawed and processed in the same manner as all study
serum samples included in each ELISA run and the same
serum pool was used throughout the study. Absorbances
were corrected for the fluctuation in seroreactivity of this
serum pool as previously described [14].
Seroreactivity was expressed as normalized absorbance
ratios (NAR) by dividing the mean blank-subtracted
(net) optical densities (ODs) by the equivalent values
of the control serum pool included in the same plate
in triplicate, using different dilutions. An average NAR
(AvgNAR) for each serum sample was then calculated
based on two dilutions: AvgNAR = (NAR10+ NAR50)/2,
where NAR10 and NAR50 are the results with the 1:10
and 1:50 dilutions, respectively. In a previous report we
described the reproducibility of the assay and calculation
of seroreactivity and demonstrated that this method is
suitable to minimize measurement error in ELISA assays
[14]. We arbitrarily defined a high level of seroreactivity
as one in the upper quintile of the distribution of AvgNAR
results.
Since our goal was to investigate the correlates of ser-
oreactivity at baseline in the cohort, only the serum sam-
ples from the first two visits were considered. Of the
2462 eligible subjects at the enrollment visit, 2185 sub-
jects were followed up at the second visit, 4 months
later. Serological results were available for 1745 and
1656 women in the first and second visits, respectively.
To maximize the availability of serological data for ana-
lysis we imputed to the woman the serological result
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from the second visit if the one for the enrollment
visit was missing, which resulted in 304 imputations.
Therefore, a total of 2049 subjects had baseline IgG ser-
oreactivity anti-HPV16, under the assumption that in
a 4-month period there would not be any important
fluctuations in serological results. Questionnaire-based
information was derived from the interviews conducted
at the enrollment visit.
HPV DNA detection and typing
DNA was extracted from ecto- and endocervical cell sam-
ples and assessed for DNA quality by amplification of a
268-bp β-globin gene fragment [15]. MY09/11 and PGMY
PCR protocols were used for HPV detection [16,17], the
former initially for the first few visits and then replaced by
the latter in subsequent visit in the cohort. Each PCR reac-
tion included negative and positive controls. HPV typing
was performed by hybridization with individual oligo-
nucleotide probes and ambiguous results were resolved by
using restriction fragment length polymorphism analysis of
the L1-amplified fragment with a set of restriction en-
zymes. The genotypes tested included high oncogenic risk
(HR-) HPVs 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66,
68, 73, and 82, and low oncogenic risk (LR-) HPV types 6,
11, 26, 32, 34, 40, 42, 44, 53, 54, 57, 61, 62, 67, 69, 70, 71,
72, 81, 83, 84, and 89 (unknown types considered LR-
HPVs) [18,19]. Specimens were tested blindly with respect
to all other subject-specific results and precautions were
taken to prevent contamination. Samples that were nega-
tive for both HPV and β-globin were considered inad-
equate for analysis. Only the HPV genotype results at the
first visit were considered in the current analysis.
Viral load
Quantification of viral load in HPV-positive samples was
performed by low-stringency PCR with HPV generic
GP5/6 primers [20,21]. DNA from cervical cell lines
Caski and HeLa were included in every assay as positive
controls. Standards were also included to enable the
quantification of viral load, and consisted of mixtures
containing varying amounts of HPV16 reference plasmid
added to a constant background of normal human DNA
(corresponding to 4, 20, 100, 500, and 2,500 viral copies
per cell, assuming a diploid genome). In low stringency
conditions these primers amplify a specific L1 region in
the HPV genome and a human genome sequence. The
signal strength of the two silver-stained gel bands was
quantified by densitometry. The logarithm of the ratio
between these two bands is directly proportional to the
logarithm of the amount of HPV DNA in individual
samples; linear interpolation in a standard curve con-
structed with the results from control mixtures allows
proper quantification of viral load expressed in viral cop-
ies per cell harboring a diploid genome.
Statistical analysis
The associations between HPV16 serological reactivity
and socioeconomic determinants, lifestyle factors, repro-
ductive health factors, or clinical and viral characteristics
were measured by unconditional logistic regression. We
calculated odds ratios (OR) and respective 95% confi-
dence intervals (CI) to gauge the magnitude and preci-
sion of the associations. Age and HPV16 DNA positivity
were considered potential confounders or mediators and
were thus included as covariates to be adjusted for in all
exploratory models. Age was considered as 4 categories
(18–24, 25–34, 35–44, and 45+ years). We also sought
to identify a subset of independent correlates of anti-
HPV16 seroreactivity via a stepwise multivariate logistic
regression strategy with backwards elimination of vari-
ables (p = 0.15 for elimination). We used STATA statis-
tical software (version 10.0) in all analyses.
Results
To analyze the predictors of serological response in the
cohort, we arbitrary selected the top 20% of seroreactiv-
ity results of 2049 women who had HPV16 serological
results. Consequently we identified 425 women for the
purpose of the current analysis.
Table 1 shows the associations between HPV16 seror-
eactivity and sociodemographic variables. Seroreactivity
increased significantly with age, and decreased with higher
levels of education and income, albeit non-significantly.
These associations were not attenuated upon adjustment
for cervical HPV16 DNA positivity.
Table 2 shows the associations with lifestyle and sexual
risk factors. Current smoking is associated with a mod-
erate decrease in likelihood of being strongly seroreac-
tive for HPV16. As expected, seroreactivity increases
when risk factors that reflect HPV exposure are con-
sidered, particularly those that indicate long-term, cu-
mulative effects, such as lifetime number of partners
and age at first intercourse. Frequency of sex but not
recent partners was associated with an increase in strong
seroreactivity, also in a dose–response manner as markers
of cumulative exposure. Practice of oral or anal sex was
not related to seroreactivity. All significant associations
persisted after controlling for age and HPV16 DNA
positivity.
Results for reproductive health characteristics that could
influence HPV seroreactivity are presented in Table 3.
To analyze possible hormonal or artifactual influences
from menstrual cycle, we classified women according to
the time between onset of last menstrual period and
date of specimen collection as follicular phase (before
14 days) or luteal phase (after 14 days). Parity was asso-
ciated significantly with having a strong anti-HPV16 re-
sponse in a dose–response manner. However, this effect
was considerably attenuated and lost statistical significance
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upon adjustment for age and HPV DNA positivity. No
other factors were significantly associated with seroreactiv-
ity, regardless of analytical framework.
We also analyzed the associations between cervical
HPV findings at enrollment and serological response
to HPV16. Table 4 presents crude and age-adjusted
ORs for positivity for cervical HPV DNA of different
HPV types and examines the potential effect of single
versus multiple infections, viral load, and infection by
HPV types in HPV16-related (i.e., Alphapapillomavirus
9 species, which also includes HPV types 31, 33, 35,
52, 58, 67) as well as unrelated phylogenetic groupings
(i.e., Alphapapillomavirus species 7, 3, 15). There was
a strong association between being HPV16 DNA posi-
tive in the cervix and having high anti-HPV16 seror-
eactivity (age-adjusted OR = 3.86, 95%CI: 2.23-6.59).
Partitioning this association between cases in which
HPV16 was the sole type in the cervical sample and
those in which it was found in coinfection with other
types did not materially change the strength of the as-
sociation (Table 4). There was no clear indication that
the quantity of HPV16 DNA in the cervix was associated
with seroreactivity; after controlling for age the strength
of the association was as strong for women with less
than one viral copy per cell as for those with more than
100 copies per cell. Serological response to HPV16
seemed to be mostly type-restricted since there was
little to no evidence that infection with types other than
HPV16 (except for phylogenetically-related Alphapa-
pillomavirus 9 types) exerted any influence on HPV16
seroreactivity.
Finally, we attempted to identify the most parsimoni-
ous set of correlates of HPV16 seroreactivity via multi-
variate analyses. As shown in Table 5, model 1 includes
all variables that were associated with seroreactivity in
univariate or bivariate models. Model 2 is the minimum
set of independent predictors after backwards elimin-
ation. Even when accounting for cervical HPV16 DNA
positivity (as a binary variable, as indicators of mono
and coinfections, or as viral load [data not shown]) ser-
oreactivity increased monotonically with age (p value for
trend <0.001) and with markers of increased sexual risk
behaviors such as lifetime sexual partners, early age of
first intercourse, and frequency of sex.
Table 1 Associations between sociodemographic variables and serological reactivity for HPV16
Characteristic and categories HPV16 seroreactivity
425/1624 (%)*
OR (95%CI)**
Unadjusted Adjusted (HPV16 and age)
Age:
<25 64/344 (15.7) 1.0 1.0
25-34 161/646 (20.0) 1.33 (0.97-1.84) 1.38 (0.97-1.84)
35-44 136/471 (22.4) 1.55 (1.11-2.15) 1.60 (1.15-2.23)
45+ 64/163 (28.2) 2.11 (1.42-3.12) 2.16 (1.45-3.22)
Ethnicity:
White 226/900 (20.1) 1.0 1.0
Non-white 139/479 (22.5) 0.87 (0.69-1.08) 0.84 (0.68-1.06)
Marital Status:
Single 49/162 (23.2) 1.0 1.0
Married/With partner 330/1339 (19.8) 0.81 (0.58-1.14) 0.76 (0.58-1.14)
Widowed/Separated 46/122 (27.4) 1.24 (0.78-1.98) 1.01 (0.54-1.09)
Education:
<Elementary 114/345 (24.8) 1.0 1.0
Elementary 240/964 (19.9) 0.75 (0.58-0.97) 0.81 (0.62-1.05)
High School 63/262 (19.4) 0.72 (0.51-1.02) 0.85 (0.59-1.21)
College/University 8/51 (13.6) 0.47 (0.21-1.03) 0.51 (0.23-1.12)
Income Quartiles:
1st Quartile 112/359 (23.8) 1.0 1.0
2nd Quartile 114/431 (20.9) 0.84 (0.63-1.13) 0.88 (0.65-1.18)
3rd Quartile 92/406 (18.5) 0.73 (0.53-0.98) 0.71 (0.52-0.97)
4th Quartile 94/399 (19.1) 0.75 (0.55-1.02) 0.74 (0.54-0.99)
*Frequencies above and below the threshold for the top 20% quintile and percentage with high seroreactivity; **Odds ratios and respective 95% confidence
intervals. First category in each variable is the referent.
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Table 2 Associations between lifestyle factors and serological reactivity for HPV16
Characteristic and categories HPV16 seroreactivity
425/1624 (%)*
OR (95%CI)**
Unadjusted Adjusted (HPV16 and age)
Smoking:
Never 216/768 (22.0) 1.0 1.0
Current 124/581 (17.6) 0.75 (0.59-0.97) 0.74 (0.58-0.98)
Former 85/275 (23.6) 1.09 (0.82-1.46) 1.06 (0.79-1.42)
Smoking duration:
Never 216/768 (22.0) 1.0 1.0
<=10 years 86/379 (18.5) 0.81 (0.61-1.07) 0.81 (0.61-1.07)
11+ years 95/413 (18.7) 0.82 (0.62-1.07) 0.62 (0.57-0.98)
Drinking:
Never 131/556 (19.1) 1.0 1.0
Ever drinker 291/1064 (21.5) 1.16 (0.92-1.47) 1.16 (0.92-1.47)
Lifetime sexual partners:
0-1 132/770 (14.6) 1.0 1.0
2-3 162/555 (22.6) 1.70 (1.32-2.19) 1.70 (1.32-2.20)
4-5 84/181 (31.7) 2.71 (1.97-3.72) 2.56 (1.97-3.53)
6+ 47/117 (28.7) 2.34 (1.59-3.44) 2.29 (1.55-3.37)
Sexual partners, last 5 years:
0-1 321/1262 (20.3) 1.0 1.0
2-3 83/290 (22.2) 1.12 (0.86-1.48) 1.17 (0.88-1.55)
4+ 20/71 (22.0) 1.10 (0.66-1.84) 1.30 (0.77-2.19)
Sexual partners, last year:
0-1 400/1534 (20.7) 1.0 1.0
2-3 15/69 (17.9) 0.83 (0.47-1.47) 0.90 (0.51-1.60)
4+ 2/5 (28.6) 1.53 (0.29-7.93) 1.89 (0.36-9.87)
Age at first sexual intercourse:
20-50 89/446 (16.6) 1.0 1.0
18-19 89/344 (20.6) 1.30 (0.93-1.79) 1.52 (1.08-2.13)
16-17 107/417 (20.4) 1.29 (0.94-1.76) 1.60 (1.15-2.23)
<=15 140/417 (25.1) 1.68 (1.25-2.27) 2.18 (1.59-3.00)
Frequency of sex (weekly):
0-1 times 224/865 (20.6) 1.0 1.0
2-3 133/576 (18.8) 0.89 (0.70-1.13) 0.95 (0.75-1.22)
4-5 42/123 (25.5) 1.31 (0.90-1.92) 1.53 (1.04-2.26)
6+ 25/58 (30.1) 1.66 (1.01-2.72) 1.77 (1.07-2.92)
Practice of anal sex:
Never 254/1018 (20.0) 1.0 1.0
Ever 171/606 (22.0) 1.13 (0.91-1.41) 1.14 (0.92-1.42)
Practice of oral sex:
Never 195/739 (20.9) 1.0 1.0
Ever 230/885 (20.6) 0.98 (0.79-1.22) 1.08 (0.87-1.34)
*Frequencies above and below the threshold for the top 20% quintile and percentage with high seroreactivity; **Odds ratios and respective 95% confidence
intervals. First category in each variable is the referent.
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Discussion
In this study we analyzed the epidemiologic correlates of
strong anti-HPV16 seroreactivity at the enrollment visits
of women from the Ludwig-McGill Cohort Study. We
defined the serological reactivity as strong if the subject’s
average NAR was in the upper quintile of anti-HPV16
ELISA seroreactivity. This definition is probably more
stringent than methods used in early reports, but associ-
ations with similar factors were identified. Our results
revealed that strong HPV16 seroreactivity increased with
age, and other factors that reflect HPV exposure, as
number of lifetime sexual partners, younger age at first
intercourse and higher frequency of sex.
The association of HPV16 serology with increasing
number of sexual partners is well known [8,22,23]. We
also observed a positive association between seroreactiv-
ity and lifetime number of sexual partners but not with
number of recent sexual partners. This is in line with
the fact that serology reflects HPV exposures that may
have occurred cumulatively since the onset of sexual be-
havior, whereas current HPV DNA positivity reflects re-
cent sexual exposure. Indeed, in previous analysis of this
cohort, women with a greater number of sexual partners
were more likely to have HPV infection, but likelihood
of infection was more strongly influenced by the recent
history of sexual activity [24]. Moreover, one cannot
exclude the possibility that HPV infections in other ana-
tomic sites could influence HPV seroreactivity, as previ-
ously described in a cohort study of HPV infection in
men [25].
In our analysis, seroreactivity increased with age. Al-
though this association was not consistently found in other
investigations [23,26], associations at specific age categories
(e.g., 30–44 ys) were observed by other authors [8]. The
Table 3 Associations between reproductive health characteristics and serological reactivity for HPV16
Characteristic and categories HPV16 seroreactivity
425/1624 (%)*
OR (95%CI)**
Unadjusted Adjusted (HPV16 and age)
Oral Contraceptives:
Never 60/264 (18.5) 1.0 1.0
<6 years 235/885 (21.0) 1.17 (0.85-1.60) 1.21 (0.88-1.67)
6+ years 130/475 (21.5) 1.20 (0.86-1.69) 1.07 (0.76-1.51)
Inter-uterine Device (IUD):
Never 281/1010 (21.8) 1.0 1.0
Ever 144/614 (19.0) 0.84 (0.67-1.05) 0.88 (0.70-1.10)
Condom Use:
Never 177/600 (22.8) 1.0 1.0
Rarely 144/574 (20.1) 0.85 (0.66-1.09) 0.88 (0.66-1.08)
Sometimes/always 98/423 (18.8) 0.78 (0.59-1.02) 0.84 (0.63-1.12)
Menstrual Cycle***:
Follicular phase 185/745 (19.9) 1.0 1.0
Luteal phase 136/526 (20.5) 1.04 (0.81-1.33) 1.04 (0.81-1.34)
Parity:
0-1 55/277 (16.6) 1.0 1.0
2-4 237/943 (20.1) 1.27 (0.92-1.74) 1.16 (0.83-1.61)
5+ 133/389 (25.5) 1.72 (1.21-2.44) 1.38 (0.94-2.01)
Abortion:
No abortion 216/804 (21.2) 1.0 1.0
One abortion 96/338 (22.1) 1.05 (0.80-1.38) 0.99 (0.75-1.31)
2+ abortions 77/262 (22.7) 1.09 (0.81-1.47) 0.98 (0.72-1.33)
Vaginal Douching:
Never/occasional 379/1457 (20.6) 1.0 1.0
Frequent 26/95 (21.5) 1.06 (0.67-1.66) 1.06 (0.67-1.67)
*Frequencies above and below the threshold for the top 20% quintile and percentage with high seroreactivity; **Odds ratios and respective 95% confidence intervals.
First category in each variable is the referent; ***At the time of specimen collection: follicular (before 14 days) and luteal phase (after 14 days). Post-menopausal women
and women with irregular cycles were not included in the analysis.
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association we observed with education and income, albeit
non-significant upon adjustment, has not been observed in
previous studies [23].
Although the Ludwig-McGill study is based on a
multiple-measurement, prospective cohort investigation
we focused on determinants of baseline seroreactivity
using only serological results from a single time point
(the enrollment visit), which prevented us from consider-
ing duration of infection in the analyses. This limitation in
our ability to define when infections began prevented us
from understanding the timing for serological responses to
become observable following the initial exposure. Never-
theless, we observed a positive correlation between HPV16
seroreactivity and HPV16 DNA positivity alone or in coin-
fection with other types with strong evidence of type-
restricted responses. We also observed some degree of
cross-reactivity for infection with other types in Alphapa-
pillomavirus 9 species (excluding HPV16), which can be
expected because of the similarity of antigenic epitopes in
L1 and L2 for members of that species.
Table 4 Associations between cervical HPV infection findings and serological reactivity for HPV16




HPV16 DNA No 398/1593 (20.0) 1.0 1.0
Yes 27/30 (47.4) 3.60 (2.11-6.13) 3.86 (2.23-6.59)
HPV16 DNA Negative 398/1593 (20.0) 1.0 1.0
Single infection 19/20 (48.7) 3.80 (2.01-7.19) 3.93 (2.07-7.48)
Other types present 8/10 (44.4) 3.20 (1.25-8.17) 3.69 (1.44-9.47)
HPV16 viral load*** Negative 398/1593 (20.0) 1.0 1.0
<1 8/11 (42.1) 2.91 (1.16-7.28) 3.10 (1.23-7.79)
1-100 12/13 (48.0) 4.33 (1.96-9.58) 4.64 (2.09-10.3)
100+ 7/6 (53.9) 3.43 (1.14-10.3) 3.73 (1.24-11.2)
HPV18 DNA No 423/1605 (20.9) 1.0 1.0
Yes 2/18 (10.0) 0.42 (0.10-1.82) 0.45 (0.10-1.96)
HPV31 DNA No 420/1604 (20.8) 1.0 1.0
Yes 5/19 (20.8) 1.01 (0.37-2.71) 1.18 (0.43-3.21)
HPV33 DNA No 423/1616 (20.8) 1.0 1.0
Yes 2/7 (22.2) 1.09 (0.23-5.27) 1.13 (0.23-5.52)
HPV6/11 DNA No 420/1606 (98.9) 1.0 1.0
Yes 5/17 (1.1) 1.12 (0.41-3.06) 1.26 (0.46-3.44)
Non HPV16 Alpha PV 9**** No 400/1574 (20.3) 1.0 1.0
Yes 25/50 (33.3) 2.00 (1.20-3.21) 2.17 (1.32-3.56)
Alpha PV 7 No 412/1566 (20.8) 1.0 1.0
Yes 13/58 (18.3) 0.85 (0.46-1.57) 0.90 (0.49-1.67)
Alpha PV 3/15 No 416/1584 (20.8) 1.0 1.0
Yes 9/40 (18.4) 0.86 (0.41-1.78) 0.87 (0.41-1.81)
Any HPV No 338/1371 (19.8) 1.0 1.0
Yes 87/252 (25.7) 1.40 (1.07-1.83) 1.52 (1.15-1.83)
Any HPV (non-HPV16) No 338/1371 (19.8) 1.0 1.0
Yes 60/222 (21.3) 1.10 (0.80-1.49) 1.19 (0.88-1.64)
Any HR-HPV No 363/1466 (19.9) 1.0 1.0
Yes 62/157 (28.3) 1.60 (1.16-2.19) 1.73 (1.25-2.39)
Any LR-HPV No 400/1528 (20.8) 1.0 1.0
Yes 25/95 (20.8) 1.00 (0.63-1.58) 1.06 (0.67-1.67)
*Frequencies above and below the threshold for the top 20% quintile and percentage with high seroreactivity; **Odds ratios and respective 95% confidence
intervals. First category in each variable is the referent; ***Number of copies per cell; ****Alphapapillomavirus species 9 and other groupings: see text for details;
viral load.
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Porras and colleagues (2010) reported that a high viral
load for HPV16 is positively correlated with anti-HPV16
antibody titer, suggesting that seroconversion could be
a consequence of an increase in antigen exposure [27]. We
have not observed such a correlation; anti-HPV16 seror-
eactivity was uniformly high even for low HPV16 viral load
levels. One possible explanation is that harboring a high
viral load could reflect inability to control viral infection.
The relation between the use of contraceptives and HPV
seropositivity has been controversial. In our study, nei-
ther use of contraceptives (oral, intra-uterine device or
condom), nor parity were significant determinants of ser-
oreactivity. A positive influence of hormonal contracep-
tives on HPV16 seropositivity was described before [23].
Specifically for HPV16, other studies described elevated
risk of seropositivity with oral contraceptive use [22,28].
We have found that current and prolonged smoking is as-
sociated with decreased HPV16 seroreactivity, and similar
associations were already described [22,26]. This could be
a reflex of the immunosuppressive effect of smoking.
Conclusion
On the basis of this cross-sectional analysis we observed
that strong baseline seroreactivity was positively corre-
lated with age, lifetime number of sexual partners, fre-
quency of sex, and HPV16 viral load, and negatively
associated with duration of smoking. Taken together our
data suggest that HPV16 seroreactivity is determined by
factors that reflect viral exposure.
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Table 5 Multivariate models for correlates of HPV16
seroreactivity*
Variable Categories Model 1 Model 2
Age (years) <25 1.0 1.0
25-34 1.36 (0.94-1.97) 1.52 (1.1-2.2)
35-44 1.73 (1.15-2.61) 1.91 (1.28-2.87)
45+ 2.41 (1.48-3.93) 3.07 (1.86-5.06)
Income 1st Quartile 1.0
2nd Quartile 0.88 (0.63-1.23)
3rd Quartile 0.81 (0.58-1.13)
4th Quartile 0.78 (0.57-1.06)
Smoking duration Never 1.0
<10 years 0.71 (0.52-0.95)




2-3 1.76 (1.33-2.32) 1.44 (1.05-1.96)
4-5 2.69 (1.89-3.84) 2.06 (1.39-3.05)
6+ 2.18 (1.40-3.4) 1.74 (1.09-2.79)
Age at first sexual
intercourse
20-50 1.0 1.0
18-19 1.50 (1.05-2.14) 1.46 (1.00-2.12)
16-17 1.41 (0.98-2.03) 1.36 (0.94-1.96)




2-3 1.07 (0.83-1.39) 1.05 (0.79-1.38)
4-5 1.63 (1.07-2.47) 1.60 (1.05-2.45)
6+ 1.57 (0.96-2.66) 1.72 (1.01-2.94)






HPV16 viral load Negative 1.0 1.0
<1 2.42 (0.88-6.76) 4.16 (1.35-12.78)
1-100 4.19 (1.84-9.56) 4.03 (1.48-10.45)




HPV16 alone 3.53 (1.76-7.10)
HPV16 + other type 3.30 (1.25-8.63)
*Model 1: Mutually adjusted for all variables shown; model 2: most parsimonious
set of independently explanatory variables via stepwise regression with backwards
elimination (due to collinearity issues between HPV16 and viral load, only HPV16
viral load was retained as covariate for the models shown).
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